Mataró, Barcelona, Spain and Charleroi, Belgium, October 14, 2019

Minoryx Therapeutics, a company specializing in the development of innovative treatments for orphan Central Nervous System (CNS) diseases, today announces that its management team will participate in the two upcoming investor conferences:

• Solebury Trout 5th Private Company Showcase featuring presentations, panels, and 1x1s with select private biotech companies on Friday, October 18, 2019 at Davis Polk & Wardwell in New York City (USA). Minoryx’ CEO to present at 1:40pm-2:00pm.
• 10th Jefferies London Healthcare Conference to be held at the Waldorf Hilton in London on November 20-21, 2019. The two-day event will include concurrent tracks of company presentations, thematic panel discussions, and 1x1/small-group meetings. This global gathering of leading healthcare executives and institutional, private equity and venture capital investors will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare.

About Minoryx Therapeutics

Minoryx is a clinical stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs. The company’s lead program, leriglitazone (MIN-102), a novel, selective PPARγ agonist, is currently being evaluated in X-ALD and Friedreich’s Ataxia. The company is backed by a syndicate of experienced investors and has support from a network of other organizations. Minoryx was founded in 2011, has operations in Spain and Belgium and has raised a total of €50M through Series A & B financing rounds. www.minoryx.com    

Media Contacts & Analysts

Andrew Lloyd & Associates Jo Reeder – Juliette dos Santos jo@ala.com / juliette@ala.com @ALA_Group + 44 1273 675 100